Travere Therapeutics Stock Soars Pre-Market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).
The FDA is expected to decide on the company's application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by proteinuria that leads to progressive kidney function loss and kidney failure, the company said.
Shares of the company soared 16% in the pre-market session.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment